Human Stem Cell Institute, Russia   Report issue

Academic/Hospital Phase 4
Founded: Russian Federation (2003)

Organization Overview

First Clinical Trial
2010
NCT03068585
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

Cambiogenplasmid (neovasculgen) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ischemia (Phase 4)

Neoplasm Metastasis (Phase 2)

Peripheral Arterial Disease (Phase 3)

Peripheral Nerve Injuries (Phase 2)

Peripheral Vascular Diseases (Phase 3)

Raynaud Disease (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 1